IsoRay, Inc. announced that it received a five year extension to its CE mark covering IsoRay's entire product offering of Cesium-131 seeds, permitting sale in the European market of these products into 2018. The CE mark designates that the manufacturer conforms with the essential product requirements of the applicable European Commission directives. Granted after a rigorous evaluation process, the CE mark allows a product to be legally marketed in the European Free Trade Association (EFTA) member states as well as the European Union.

The GliaSite(R) radiation therapy is exclusively marketed worldwide by IsoRay, which is also the exclusive manufacturer of Cesium-131 in seed form. With the recently announced FDA clearance for liquid cesium-131, IsoRay can now offer multiple isotope options for use within the GliaSite(R) catheter. Cesium-131 allows for the internal radiation treatment of many different cancers because of its unique combination of high energy and unrivaled speed in providing therapeutic radiation (9.7 day half-life).